(Q42189605)

18 October 2017

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm (English)

1 reference

myeloproliferative neoplasm

18 October 2017

1 reference

5

1 reference

18 October 2017

8

1 reference

18 October 2017

Véronique Ollivier

3

0 references

Martine Jandrot-Perrus

object named as

Martine Jandrot-Perrus

9

0 references

Cecile Denis

object named as

Cécile V Denis

4

0 references

William Vainchenker

7

object named as

William Vainchenker

1 reference

18 October 2017

Lamia Lamrani

1

1 reference

18 October 2017

Catherine Lacout

2

1 reference

18 October 2017

Benoit Ho Tin Noe

6

1 reference

18 October 2017

language of work or name

English

0 references

publication date

20 June 2014

1 reference

18 October 2017

1 reference

18 October 2017

124

1 reference

18 October 2017

7

1 reference

18 October 2017

1136-1145

1 reference

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

18 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Red blood cells mediate the onset of thrombosis in the ferric chloride murine model.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Thrombotic disease in the myeloproliferative neoplasms.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Diverging signaling events control the pathway of GPVI down-regulation in vivo

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

A gain-of-function mutation of JAK2 in myeloproliferative disorders

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Increased thromboxane biosynthesis in essential thrombocythemia.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Platelet von Willebrand factor abnormalities in myeloproliferative syndromes

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

GPVI levels in platelets: relationship to platelet function at high shear

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133486

High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice

17 August 2018

1 reference

12 December 2020

Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia

1 reference

12 December 2020

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders

1 reference

12 December 2020

Endothelial dysfunction in patients with polycythaemia vera

1 reference

12 December 2020

Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders

1 reference

12 December 2020

Evidence for a platelet membrane defect in the myeloproliferative syndromes

1 reference

12 December 2020

Acquired von Willebrand's disease in the myeloproliferative syndrome

1 reference

12 December 2020

Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis

1 reference

12 December 2020

Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders

1 reference

12 December 2020

Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma

1 reference

12 December 2020

Increased platelet CD36 constitutes a common marker in myeloproliferative disorders

1 reference

12 December 2020

Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis

1 reference

12 December 2020

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

12 December 2020

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

1 reference

12 December 2020

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence andJAK2 V617F allele burden

1 reference

12 December 2020

Mechanisms underlying FeCl3-induced arterial thrombosis

1 reference

12 December 2020

10.1182/BLOOD-2013-10-530832

Identifiers

DOI

1 reference

18 October 2017

1 reference

18 October 2017

PubMed publication ID

24951423

1 reference